Caris Life Sciences, Inc.

As of June 30, 2026, Caris Life Sciences, Inc. carries a market capitalization of 4.41B, placing it among publicly traded companies globally. Its enterprise value stands at 4.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Caris Life Sciences, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Caris Life Sciences, Inc. has 282.58M shares outstanding.

As of June 30, 2026, Caris Life Sciences, Inc. trades at a trailing price-to-earnings ratio of 47.88. The price-to-sales ratio is 5.09, and the price-to-book ratio stands at 8.51.

As of June 30, 2026, Caris Life Sciences, Inc. trades at an EV/EBITDA multiple of 26.98 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 30.64 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.11B versus a market cap of 4.41B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Caris Life Sciences, Inc. maintains a current ratio of 5.53, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.45, indicating elevated leverage, while an interest coverage ratio of 3.71 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. posted a return on equity (ROE) of 20.13, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 9.62, measuring how efficiently the asset base is converted into earnings. The company generates approximately 469,231.45 in revenue per employee across its workforce of 1,846.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.65 indicates how many times Caris Life Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. recorded an income tax benefit of -97,158.30 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 91.93M, leaving 92.02M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Caris Life Sciences, Inc.'s stock has gained approximately 9.23% over the past 52 weeks. The 50-day moving average sits at 24.42, while the 200-day moving average is 18.54.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. generated 866.20M in revenue and converted that into 92.02M in net income, yielding earnings per share of 0.32. EBITDA reached 152.32M, while operating income came in at 134.15M.

As of June 30, 2026, Caris Life Sciences, Inc. holds 694.21M in cash and equivalents against 395.99M in total debt, resulting in a net debt position of -260.63M. Total book value stands at 517.94M, with working capital of 758.35M providing operational flexibility.

Caris Life Sciences, Inc. produced 147.54M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -19.72M in capital expenditures, free cash flow totaled 127.82M - equivalent to 0.45 per share.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. posted a gross margin of 69.66, reflecting its pricing power and cost economics. The operating margin of 15.49 and net profit margin of 10.62 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.83, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Caris Life Sciences, Inc. shareholders.

As of June 30, 2026, Caris Life Sciences, Inc. has an Altman Z-Score of 3.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.